By preventing this immune checkpoint interaction, pembrolizumab restores T cell-mediated tumor recognition and elimination, demonstrating particular efficacy in advanced or recurrent PD-L1-positive cervical cancer cases (46, 48). This evidence concerns the gene CD274 and cervical carcinoma.